Monitor for any follow-up insider sales in the coming weeks, a single C-suite sell of $1.15M is routine, but a sustained cluster of additional C-suite sells would warrant closer attention.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 14 $38.86entry
- T+1 · 2mo ago −2.06%α −1.60% · $38.06
- T+5 · 8w ago −7.31%α −7.41% · $36.02
- T+20 · 5w ago −20.51%α −22.77% · $30.89
- T+45 · todayOpen
- T+60 · in 21d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharvaris N.V. (PHVS), insider cluster of 3 sells totaling $2.06M over the last 7 days, led by Chief Early Development officer Anne Lesage (30.0K shares @ $38.30, $1.15M). All transactions are open-market sales (code S). No buys in the cluster. The cluster is C-suite weighted (Chief Early Development officer), but the total dollar value is modest relative to the $2.6B market cap (~0.08%), falling below the 0.1% materiality threshold, this is a routine, liquidity-driven cluster. Per the asymmetric calibration, cluster sells are NOT amplified because they often cluster around shared vesting dates or blackout-window openings. Sentiment is neutral with a slight negative tilt given the C-suite involvement, but the dollar amount is too small to be material.
Key Financial Metrics
Financial Impact
Not specified
Risk Factors
- Insider sales may signal management's view of near-term valuation, though the dollar amount is small relative to market cap
- Biotech sector volatility, clinical trial results or regulatory news could move the stock significantly
- Cluster sells are often driven by vesting schedules and blackout windows, not necessarily bearish sentiment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PHVS-1789403417374 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers